FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2473386911> ?p ?o ?g. }

• W2473386911 endingPage "10535" @default.
• W2473386911 startingPage "10535" @default.
• W2473386911 abstract "10535 Background: The oral TKI ponatinib has potent pre-clinical activity against mutant KIT and PDGFRA, including clinically relevant mutants resistant to available TKIs. We hypothesized that ponatinib might be effective in GIST after prior TKI treatment failure. Methods: This phase 2, single-arm study (NCT01874665) evaluated efficacy and safety of ponatinib 45 mg qd in advanced GIST after TKI failure; N = 45. Cohorts were enrolled based on presence (A) or absence (B) of KIT exon 11 mutations. Primary endpoint is clinical benefit rate (CBR = CR + PR + SD) at 16 wk by modified RECIST 1.1 in Cohort A. Secondary endpoints include CBR (Cohort B and overall) and objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Due to arterial occlusive events in other ponatinib trials, enrollment criteria were revised in early 2014 to include only pts in whom all 3 TKIs approved for GIST had failed. Results: Enrollment is complete (Cohort A, 30 pts; B, 15 pts). Median age was 59 y. Most pts (76%) received ≥4 anticancer regimens; 36% received 2 and 58% received 3 approved TKIs. Median time since diagnosis was 6 y. At 10-mo median follow-up (data as of Dec 1, 2014), 9 pts were ongoing; 15 discontinued for progressive disease per RECIST, 9 for AEs, and 12 for other reasons. Cohort A CBR was 37% (10/27); ORR 7% (2/27). Best responses: PR 2; SD 16. Median PFS/OS: 4.3 mo/15.0 mo. Cohort B CBR was 14% (2/14); ORR 0%. Best response: SD 6. Median PFS/OS: 2.0 mo/13.5 mo. Treatment-emergent AEs (TEAEs) in ≥40% of pts: rash 58%; fatigue 51%; constipation 42%; headache 42%; myalgia 40%. Myocardial ischemia, cerebrovascular accident, peripheral artery stenosis, deep vein thrombosis, and pulmonary embolism occurred in 1 pt each; 4 pts had evidence of ventricular dysfunction. Serious TEAEs (other than disease progression) in ≥2 pts: abdominal pain 9%; pneumonia 7%; fatigue, nausea, small intestinal obstruction, vomiting, 4% each. Two deaths, from pneumonia and pulmonary embolism, were considered possibly ponatinib-related. Conclusions: Ponatinib has clinical activity in advanced GIST pts after TKI failure, particularly pts with KIT exon 11 mutations. Clinical trial information: NCT01874665." @default.
• W2473386911 created "2016-07-22" @default.
• W2473386911 creator A5038563211 @default.
• W2473386911 creator A5040359760 @default.
• W2473386911 creator A5043983803 @default.
• W2473386911 creator A5060580923 @default.
• W2473386911 creator A5069671246 @default.
• W2473386911 creator A5078289621 @default.
• W2473386911 creator A5085336500 @default.
• W2473386911 creator A5091057405 @default.
• W2473386911 date "2015-05-20" @default.
• W2473386911 modified "2023-10-02" @default.
• W2473386911 title "Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study." @default.
• W2473386911 doi "https://doi.org/10.1200/jco.2015.33.15_suppl.10535" @default.
• W2473386911 hasPublicationYear "2015" @default.
• W2473386911 type Work @default.
• W2473386911 sameAs 2473386911 @default.
• W2473386911 citedByCount "10" @default.
• W2473386911 countsByYear W24733869112017 @default.
• W2473386911 countsByYear W24733869112019 @default.
• W2473386911 countsByYear W24733869112020 @default.
• W2473386911 countsByYear W24733869112021 @default.
• W2473386911 countsByYear W24733869112022 @default.
• W2473386911 crossrefType "journal-article" @default.
• W2473386911 hasAuthorship W2473386911A5038563211 @default.
• W2473386911 hasAuthorship W2473386911A5040359760 @default.
• W2473386911 hasAuthorship W2473386911A5043983803 @default.
• W2473386911 hasAuthorship W2473386911A5060580923 @default.
• W2473386911 hasAuthorship W2473386911A5069671246 @default.
• W2473386911 hasAuthorship W2473386911A5078289621 @default.
• W2473386911 hasAuthorship W2473386911A5085336500 @default.
• W2473386911 hasAuthorship W2473386911A5091057405 @default.
• W2473386911 hasConcept C126322002 @default.
• W2473386911 hasConcept C141071460 @default.
• W2473386911 hasConcept C143998085 @default.
• W2473386911 hasConcept C16930146 @default.
• W2473386911 hasConcept C203092338 @default.
• W2473386911 hasConcept C2775922572 @default.
• W2473386911 hasConcept C2776694085 @default.
• W2473386911 hasConcept C2777583451 @default.
• W2473386911 hasConcept C2778729363 @default.
• W2473386911 hasConcept C2778822529 @default.
• W2473386911 hasConcept C2779536868 @default.
• W2473386911 hasConcept C2780381907 @default.
• W2473386911 hasConcept C535046627 @default.
• W2473386911 hasConcept C71924100 @default.
• W2473386911 hasConcept C72563966 @default.
• W2473386911 hasConceptScore W2473386911C126322002 @default.
• W2473386911 hasConceptScore W2473386911C141071460 @default.
• W2473386911 hasConceptScore W2473386911C143998085 @default.
• W2473386911 hasConceptScore W2473386911C16930146 @default.
• W2473386911 hasConceptScore W2473386911C203092338 @default.
• W2473386911 hasConceptScore W2473386911C2775922572 @default.
• W2473386911 hasConceptScore W2473386911C2776694085 @default.
• W2473386911 hasConceptScore W2473386911C2777583451 @default.
• W2473386911 hasConceptScore W2473386911C2778729363 @default.
• W2473386911 hasConceptScore W2473386911C2778822529 @default.
• W2473386911 hasConceptScore W2473386911C2779536868 @default.
• W2473386911 hasConceptScore W2473386911C2780381907 @default.
• W2473386911 hasConceptScore W2473386911C535046627 @default.
• W2473386911 hasConceptScore W2473386911C71924100 @default.
• W2473386911 hasConceptScore W2473386911C72563966 @default.
• W2473386911 hasIssue "15_suppl" @default.
• W2473386911 hasLocation W24733869111 @default.
• W2473386911 hasOpenAccess W2473386911 @default.
• W2473386911 hasPrimaryLocation W24733869111 @default.
• W2473386911 hasRelatedWork W2059939877 @default.
• W2473386911 hasRelatedWork W2323173556 @default.
• W2473386911 hasRelatedWork W2474810070 @default.
• W2473386911 hasRelatedWork W2612255169 @default.
• W2473386911 hasRelatedWork W2809737726 @default.
• W2473386911 hasRelatedWork W2889990731 @default.
• W2473386911 hasRelatedWork W4224037798 @default.
• W2473386911 hasRelatedWork W4230002713 @default.
• W2473386911 hasRelatedWork W4280598799 @default.
• W2473386911 hasRelatedWork W4283741924 @default.
• W2473386911 hasVolume "33" @default.
• W2473386911 isParatext "false" @default.
• W2473386911 isRetracted "false" @default.
• W2473386911 magId "2473386911" @default.
• W2473386911 workType "article" @default.